Core Viewpoint - The company is currently facing challenges due to the chairman being under investigation, but it emphasizes that operations are normal and business activities are progressing steadily [1] Group 1: Company Operations - The company stated that its operations are normal and all business activities are progressing in an orderly manner [1] - The marketing department is closely monitoring market dynamics and will adjust marketing strategies based on market feedback to ensure effective product promotion [1] Group 2: Financial Reporting and Compliance - The company adheres to accounting standards and regulations in preparing and disclosing financial reports to ensure accuracy [1] - The management is committed to enhancing performance and company value while maintaining compliance with information disclosure obligations [1] Group 3: Strategic Focus - The company aims for steady progress while promoting innovation and diversified development to achieve high-quality and healthy growth [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 鉴于潜江永安药业股份有限公司（以下简称"公司"）及子公司总计使用最高额度不超过（含）人民币 7 亿元的自有资金进行委托理财事项的授权即将到期，为提高公司自有闲置资金的利用效率，获取一定的 投资收益，公司于2025年4月28日、2025年6月24日分别召开了第七届董事会第六次临时会议及2024年年 度股东会，审议通过了《关于使用自有资金进行委托理财的议案》，同意公司及子公司总计使用最高额 度不超过（含）人民币 7.5 亿元的自有资金进行委托理财。上述额度可滚动使用，有效期自股东会审议 通过之日起不超过 12 个月，并授权公司管理层具体实施相关事宜。公司根据上述决议，择机购买了相 关理财产品，现将有关情况公告如下： 一、理财产品的主要情况 （一）2025年7月30日，公司出资3000万元，向中国银河证券股份有限公司（以下简称"银河证券"）购 买理财产品，具体情况如下： 1、产品名称：银河盛汇尊享3号集合资产管理计划 2、产品代码：ZX1003 3、产品主要投资范围： ...

证券代码：002365 证券简称：永安药业 公告编号：2025-46 潜江永安药业股份有限公司 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2、产品代码：ZX1003 3、产品主要投资范围： 本产品仅投资于标准化资产，具体包括： （1）固定收益类资产：现金、货币市场基金、银行存款、大额存单、同业 存单，债券回购；在国务院同意设立的交易所、银行间市场发行上市交易的国债、 地方政府债、央行票据、各类金融债、企业债券、公司债、超短期融资券、短期 融资券、中期票据、资产支持票据、非公开定向融资工具、资产支持证券、可转 债、可交换债及可分离债券、债券型基金、分级基金 A 份额等。 （2）其他资产：在证券期货交易所等国务院同意设立的交易场所集中交易 清算的国债期货。 投资上述投资品种需要签署相关协议的，投资者同意管理人代表本计划签署 相关文件。 法律法规或中国证监会允许集合计划投资其他品种的，投资者、管理人在与 资产托管人协商一致并履行合同变更程序后，可以将其纳入本计划的投资范围， 并应为管理人和托管人相关系统准备以及投资组合调整留出必要的 ...

Group 1 - Liu Pharmaceutical Group plans to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 25.70 yuan per share [1] - Dongshan Precision intends to invest up to 1 billion USD to build a high-end printed circuit board project to meet the long-term demand for high-end printed circuit boards in emerging scenarios such as AI [1] - Bomaike reported a net profit of 12.39 million yuan for the first half of the year, a year-on-year decline of 80.42% [2] Group 2 - Western Mining achieved a net profit of 1.869 billion yuan in the first half of the year, a year-on-year increase of 15% [2] - Fuliwang expects a net loss of approximately 17 million yuan for the first half of the year, a decrease of 137.12% compared to the same period last year [2] - Digital Certification anticipates a net loss of between 80 million and 96 million yuan for the first half of the year, compared to a loss of 29.25 million yuan in the same period last year [3] Group 3 - Shanghai Construction reported a net profit of 710 million yuan for the first half of the year, a year-on-year decrease of 14.04% [5] - Funneng Co. achieved a net profit of 1.337 billion yuan in the first half of the year, a year-on-year increase of 12.48% [6] - Tengda Construction's total contract amount for the first half of the year decreased by 17.55% year-on-year [7] Group 4 - Fudan Fuhua decided to terminate the public transfer of a 28% stake in a subsidiary due to the lack of a deposit from potential buyers [9] - Fulei Ant's subsidiary has decided to cease operations due to intense competition in the photovoltaic industry and ongoing losses [11] - Dongfang Ocean's subsidiary received a medical device registration certificate for a folic acid testing kit [14] Group 5 - Huayu Pharmaceutical's subsidiary received overseas listing approvals for several products [16] - Feima International received a performance commitment compensation of 437 million yuan from its controlling shareholder [16] - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project with a total investment of approximately 16.66 billion yuan [16] Group 6 - Anhui Construction won the bid for the S68 Jingde to Jixi Expressway project with an estimated total investment of 5.7 billion yuan [18] - China Communications Construction Company signed new contracts worth 991.054 billion yuan in the first half of the year, a year-on-year increase of 3.14% [19] - Kehui Co. plans to use up to 70 million yuan of idle funds for cash management [22] Group 7 - Biological Shares' subsidiary received a clinical trial approval for a cat mRNA vaccine, the first of its kind in China [23] - Ruipu Biological received a clinical trial approval for a pig mRNA vaccine, which is the first economic animal mRNA vaccine in China [24] - Nanjing New Hundred's major assets were judicially frozen due to liquidity debt crisis faced by its controlling shareholder [27] Group 8 - Changshu Bank plans to merge three village banks and establish branches, pending shareholder approval [28] - Yong'an Pharmaceutical plans to reduce its holdings by up to 2.6323 million shares [29] - Zhujiang Co. received approval from the Shanghai Stock Exchange for a stock issuance to specific targets [31] Group 9 - Sanyangma's subsidiary signed a 120 million yuan procurement contract for sensor products [33] - Jintou City Development plans to purchase a villa property for approximately 7.1854 million yuan [35] - Yuanli Co. intends to acquire 100% of Tongsheng Co. through a combination of cash and stock issuance [36] Group 10 - Xin'an Century's controlling shareholder plans to reduce holdings by up to 2.22% of the company's shares [36] - Fute Technology plans to raise up to 528 million yuan through a private placement for various projects [36] - Helen Piano's actual controller is set to change, with stock resuming trading [37] Group 11 - Weiergao expects a net profit increase of 12.55% to 30.87% for the first half of the year [38] - Saiwei Microelectronics plans to transfer up to 18% of its shares through an agreement [40] - Yongli Co. intends to acquire a 22.75% stake in a subsidiary [42] Group 12 - ST Xiachuang plans to publicly transfer a 20% stake in Guangdong Yuweiji [43] - Dema Technology's shareholders plan to transfer 778.84 million shares through an inquiry [45] - Zhongshi Technology's shareholders plan to reduce holdings by up to 2.86% of the company's shares [46] Group 13 - Wufang Optoelectronics' controlling shareholder plans to reduce holdings by up to 0.93% of the company's shares [48] - Fusenmei's chairman has been detained, temporarily unable to fulfill his duties [49] - Reliable Co.'s shareholders plan to reduce holdings by a total of up to 2.63% of the company's shares [51] Group 14 - Gao Neng Environment plans to repurchase shares worth between 100 million and 150 million yuan [53]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced a share reduction plan by its controlling shareholder, Huanggang Yong'an Pharmaceutical Co., Ltd., which holds 10,529,232 shares, representing 3.64% of the total share capital after excluding shares in the repurchase account. The plan involves reducing up to 2,632,300 shares, or 0.91% of the total share capital, within three months without changing control of the company [1][2]. Financial Performance - In Q1 2025, Yong'an Pharmaceutical reported revenue of 171 million yuan, a year-on-year decrease of 12.96%. The net profit attributable to shareholders was -4.37 million yuan, down from 28.68 million yuan in the same period last year. The net profit after excluding non-recurring items was -6.67 million yuan, compared to 19.97 million yuan in the previous year [2]. - For the years 2021 to 2024, Yong'an Pharmaceutical's revenue was 1.565 billion yuan, 1.462 billion yuan, 973 million yuan, and 839 million yuan, respectively. The net profit attributable to shareholders for the same years was 111 million yuan, 140 million yuan, -12.31 million yuan, and 61.76 million yuan. The net profit after excluding non-recurring items was 91.82 million yuan, 122 million yuan, -75.99 million yuan, and 26.76 million yuan [2]. - The company expects a significant decline in net profit for the first half of 2025, projecting a range of 10.0177 million to 15.0177 million yuan, representing a decrease of 80.91% to 71.39% year-on-year. The net profit after excluding non-recurring items is expected to be between 1.8883 million and 2.8083 million yuan, down 94.75% to 92.19% year-on-year [1].

证券代码：002365 证券简称：永安药业 公告编号：2025-45 潜江永安药业股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 潜江永安药业股份有限公司（以下简称"公司"、"本公司"）控股股东、 实际控制人之一致行动人黄冈永安药业有限公司（以下简称"黄冈永安"）持有 公司股份 10,529,232 股（占剔除公司回购专用账户股份后的总股本比例 3.64%） 计划自本公告披露之日起十五个交易日后的三个月内以集中竞价交易或大宗交 易方式减持公司股份不超过 2,632,300 股（占剔除公司回购专用账户股份后的总 股本比例 0.91%），本次减持不会导致公司控制权发生变更。 公司于近日收到公司控股股东、实际控制人之一致行动人黄冈永安出具的 《股东股份减持计划告知函》，现将具体情况公告如下： 一、减持主体的基本情况 关于公司控股股东、实际控制人之一致行动人 拟减持公司股份的预披露公告 股东黄冈永安药业有限公司保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 （一）减持主体名称：黄冈永安药业有限公司。 （二）减持主体持股情况：截止本公告披 ...

永安药业(002365.SZ)公告称，公司控股股东、实际控制人之一致行动人黄冈永安药业有限公司计划自 公告披露之日起十五个交易日后的三个月内，以集中竞价交易或大宗交易方式减持公司股份不超过 263.23万股，占剔除公司 回购专用账户股份后的总股本比例0.91%。减持原因为经营需要，股份来源为 首次公开发行前持有的股份及因权益分派资本公积金转增股本的股份。本次减持不会导致公司控制权发 生变更。 ...

永安药业（002365）公告，持有1052.92万股(占剔除公司回购专用账户股份后的总股本比例3.64%)的股 东黄冈永安药业有限公司计划自本公告披露之日起15个交易日后的3个月内，通过集中竞价交易或大宗 交易方式减持公司股份不超过263.23万股(占剔除公司回购专用账户股份后的总股本比例0.91%)。 ...

Group 1: Institutional Trading Highlights - A total of 39 stocks were listed on the institutional trading leaderboard, with 20 stocks seeing net purchases and 19 stocks experiencing net sales [1] - The top three stocks with the highest net purchases by institutions were: Yipin Hong (79.39 million), Kanghong Pharmaceutical (77.90 million), and Yong'an Pharmaceutical (69.46 million) [1][2] - Yipin Hong's subsidiary, Paracetamol Sodium, has passed CDE technical review, which is a selective COX-2 inhibitor developed by the US company Pharmacia, providing anti-inflammatory and analgesic effects [2] Group 2: Major Projects and Economic Impact - The opening ceremony for the Yarlung Zangbo River downstream hydropower project was held, with significant implications for the economy, potentially showing a U-shaped impact on economic growth [3][4] - The project is expected to enhance hydropower generation, boost local economies, and promote the development of the clean energy industry, involving multiple sectors such as civil explosives, infrastructure, cement, and energy conversion [4] Group 3: Robotics Industry Developments - Changsheng Bearing is advancing its cooperation with Yuzhu Technology, having signed a cooperation agreement and secured orders [5] - Yuzhu Technology has initiated its IPO guidance with CITIC Securities and has received a significant order worth 90.51 million from Miyi (Shanghai) Automotive Technology [5] - According to IDC, Yuzhu Technology is projected to capture a 32.4% share of the global robotics market in 2024, with expected sales of 23,700 robotic dogs, accounting for approximately 69.75% of the global market [6]

永安药业今日下跌5.96%，全天换手率25.87%，成交额14.30亿元，振幅10.50%。龙虎榜数据显示，机构 净买入6674.39万元，营业部席位合计净卖出3.59亿元。 深交所公开信息显示，当日该股因日跌幅偏离值达-7.01%上榜，机构专用席位净买入6674.39万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交5.72亿元，其中，买入成交额为1.40亿 元，卖出成交额为4.32亿元，合计净卖出2.92亿元。 具体来看，今日上榜的营业部中，共有4家机构专用席位现身，即买一、买二、买三、买五、卖四，合 计买入金额1.22亿元，卖出金额5551.67万元，合计净买入6674.39万元。 （文章来源：证券时报网） 近半年该股累计上榜龙虎榜30次，上榜次日股价平均涨2.47%，上榜后5日平均涨4.54%。 资金流向方面，今日该股主力资金净流出3.77亿元，其中，特大单净流出2.86亿元，大单资金净流出 9102.98万元。近5日主力资金净流出5.61亿元。（数据宝） 永安药业7月21日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | -- ...